![Peter Sondermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Sondermann is the founder of TACALYX GmbH, serving as Chief Executive Officer since 2019.
Dr. Sondermann was the founder of SuppreMol GmbH, previously holding the title of Chief Scientific Officer since its founding in 2002.
Former positions include Head-Process Biochemistry at Roche Glycart AG and Group Leader-Structural Immunology at Max Planck Institute of Biochemistry.
Education includes undergraduate and doctorate degrees from the University of Bielefeld.
| Sociétés | Poste | Début |
|---|---|---|
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Fondateur | 01/01/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
SuppreMol GmbH
 SuppreMol GmbH Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for the treatment of autoimmune diseases | Fondateur | - |
Max Planck Institute of Biochemistry
 Max Planck Institute of Biochemistry Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that engages in research, development and commercialization of antibody-based products | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that engages in research, development and commercialization of antibody-based products | Health Technology |
University of Bielefeld
 University of Bielefeld Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SuppreMol GmbH
SuppreMol GmbH Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for the treatment of autoimmune diseases | Health Technology |
Max Planck Institute of Biochemistry
Max Planck Institute of Biochemistry Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
